Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It should be 10 days to trade over 1 dollar why not?.. if the company spend a few million dollars to soak up those cheap shares and reduce o/s it can see easily over 1 dollar..
This about 50 million shares cost with current price just 2.5 millon dollars..
They have about 29 million dollars cash..
That is not a lot of time to get SBFM back over $1 without the RS. Do you actually think that is possible?
They have time until April 25 for hearing
All sounds good, but they have an RS pending. How does SBFM overcome the pending RS keeping the price so low?
Setting up for a big run
SBFM 1 dollar plus coming. About 29 million cash, debit under 700k, 99 million o/s, Revenue increases each quarter, gross profit margin increases the company expected to post net profit this year, 46 employees, 51 generic drugs on the market..
SBFM 7 % UP volume increases
Any if any amazing products product, or nothing
Funny cash and shares outstanding
SBFM cash per share 29 cents. SBFM had 18.8 million dollars cash by end of q3 2023. Plus with recent offering they got 10 million dollars.. About 28.8 million dollars cash., the company has 99 million outstanding shares
Cash per shares $28.8 million / 99 mi,lion shares= .289 dollars.
By the way the company has under 700k debt.
https://finance.yahoo.com/quote/SBFM/
SBFM ready to skyrocket
SBFM 6 cents loading zone, cash per share 28 cents
SBFM a hearing scheduled on 25 April 2024 with Nasdaq. we have lots of time.. stay tuned! https://www.otcmarkets.com/filing/html?id=17332297&guid=58d-knzRuvJzB3h
Saw all this a while ago. Also, I've been on Nora Pharma's website many times. It all sounds good, but the PPS has continued to decline with no end in sight until today. Dropped from a high of $48 in January 2021. Now getting ready for another RS. The last one didn't go well except to get SBFM a Nasdaq listing. How does a company like this end up a $.0439 (yesterday)? The next RS is to keep them listed, but the PPS may decline again if history repeats itself!
SBFM cash per share 29 cents. SBFM had 18.5 million dollars cash by end of q3 2023. Plus recent oferr8ng they got 10 million dollars.. About 28.5 million dollars cash., the company has 99 million outstanding shares
Cash per shares $28.5 million / 99 mi,lion shares= .2878 dollars.
By the way the company has under 700k debt.
https://finance.yahoo.com/quote/SBFM/
SBFM has 51 drugs on the market
Prescription drugs
Our generic prescriptions drugs are sold through Nora Pharma Inc., our wholly-owned Canadian subsidiary.
NAME
ACTION/INDICATION
REFERENCE BRAND
Alendronate
Osteoporosis
Fosamax®
Amlodipine
Cardiovascular
Norvasc®
Apixaban
Cardiovascular
Eliquis®
Atorvastatin
Cardiovascular
Lipitor®
Azithromycin
Antibacterial
Zithromax®
Candesartan
Hypertension
Atacand®
Candesartan HCTZ
Hypertension
Atacand®
Celecoxib
Anti-inflammatory
Celebrex®
Cetirizine
Allergy
Reactine®
Ciprofloxacin
Antibiotic
Cipro®
Citalopram
Central nervous system
Celexa®
Clindamycin
Antibiotic
Dalacin®
Clopidogrel
Cardiovascular
Plavix®
Donepezil
Central nervous system
Aricept®
Duloxetine
Central nervous system
Cymbalta®
Dutasteride
Urology
Avodart®
Escitalopram
Central nervous system
Cipralex®
Ezetimibe
Cardiovascular
Ezetrol®
Finasteride
Urology
Proscar®
Flecainide
Cardiovascular
Tambocor®
Fluconazole
Antifungal
Diflucan®
Fluoxetine
Central nervous system
Prozac®
Hydroxychloroquine
Antimalarial
Plaquenil®
Lacosamide
Central nervous system
Vimpat®
Letrozole
Oncology
Femara®
Levetiracetam
Central nervous system
Keppra®
Mirtazapine
Central nervous system
Remeron®
Montelukast
Allergy
Singulair®
Olanzapine ODT
Central nervous system
Zyprexa®
Olmesartan
Cardiovascular
Olmetec®
Olmesartan HCTZ
Cardiovascular Olmetec
Plus®
Pantoprazole
Acid Reflux
Pantoloc®
Paroxetine
Central nervous system
Paxil®
Perindopril
Cardiovascular
Coversyl®
Pravastatin
Cardiovascular
Pravachol®
Pregabalin
Central nervous system
Lyrica®
Quetiapine
Central nervous system
Seroquel®
Quetiapine XR
Central nervous system
Seroquel XR®
Ramipril
Cardiovascular
Altace®
Rizatriptan ODT
Central nervous system
Maxalt® ODT
Rosuvastatin
Cardiovascular
Crestor®
Sertraline
Central nervous system
Zoloft®
Sildenafil
Urology
Viagra®
Tadalafil
Urology
Cialis®
Telmisartan
Cardiovascular
Micardis®
Telmisartan HCTZ
Cardiovascular
Micardis Plus®
Tramadol Acetaminophen
Central nervous system
Tramacet®
Zolmitriptan
Central nervous system
Zomig®
Zopiclone
Central nervous system
Imovane®
HEADQUARTERS
1177 Avenue of the Americas, 5 th Floor
New York, NY 10036
USA
Tel: 332-216-1147
MONTREAL OFFICE
6500 Trans-Canada Highway, 4th Floor
Pointe-Claire, Quebec H9R 0A5
CANADA
Tel: 514-426-6161
info@sunshinebiopharma.com
© 2023 SUNSHINE BIOPHARMA INC.
All rights reserved.
https://sunshinebiopharma.com/prescription-drugs/
"SBFM is On-Track for Profitability in 2H2024"
Sunshine Biopharma Reports Strong 3Q23 and is On-Track for Profitability in 2H2024.
Investment Highlights:
Sunshine Biopharma reported the results for its third quarter of 2023 and those results
were better than we expected. Quarterly revenue was on-track at almost $6 million,
compared to $4.3 million for the entire year of 2022. We believe the company is
progressing as hoped for and could reach profitability in 2H2024., which we would
view as a major positive achievement.
In addition, Sunshine has demonstrated better cost control than we estimated. We
expected total operating (G&A) expenses of $4.3 million for 3Q23 and the company
beat that, reporting actual operating expenses of only $2.8 million.
SBFM reported EPS of ($0.04) for Q3, handily beating our estimate of ($0.08).
Sunshine ended Q3 with $18.8 million in cash and liquid assets. This includes
spending more than $0.5 million to buy back stock.
The company also has a potentially blockbuster pipeline of three drugs in very early
stages of development; Adva-27a for pancreatic and other cancers, a PLpro inhibitor
to treat COVID-19 and the K1.1 mRNA therapeutic for liver cancer. Because these
drug candidates have not yet reached the clinical stage, we do not include them in
our price target valuation and they represent possible upside.
While the K1.1 mRNA and PLpro inhibitor programs are still on track to start Phase
1 clinical trials in 2H2024, the Adva-27a program has been delayed (see below for
details).
We see Sunshine Biopharma as being on the verge of putting together a string of
quarters with growing revenues from its generic (and OTC) drug business ramping
up from $4.3 million in 2022 to an estimated $22.5 million in 2023, $44.4 million
in 2024 and $100 million in 2025. We confirm our BUY recommedation for SBFM
shares and our $3 Target Price.
https://sunshinebiopharma.com/analysts-coverage/
Aegis Capital: SBFM target price 3 Dollars
Sunshine Biopharma Reports Strong 3Q23 and is On-Track for Profitability in 2H2024.
Investment Highlights:
Sunshine Biopharma reported the results for its third quarter of 2023 and those results
were better than we expected. Quarterly revenue was on-track at almost $6 million,
compared to $4.3 million for the entire year of 2022. We believe the company is
progressing as hoped for and could reach profitability in 2H2024., which we would
view as a major positive achievement.
In addition, Sunshine has demonstrated better cost control than we estimated. We
expected total operating (G&A) expenses of $4.3 million for 3Q23 and the company
beat that, reporting actual operating expenses of only $2.8 million.
SBFM reported EPS of ($0.04) for Q3, handily beating our estimate of ($0.08).
Sunshine ended Q3 with $18.8 million in cash and liquid assets. This includes
spending more than $0.5 million to buy back stock.
The company also has a potentially blockbuster pipeline of three drugs in very early
stages of development; Adva-27a for pancreatic and other cancers, a PLpro inhibitor
to treat COVID-19 and the K1.1 mRNA therapeutic for liver cancer. Because these
drug candidates have not yet reached the clinical stage, we do not include them in
our price target valuation and they represent possible upside.
While the K1.1 mRNA and PLpro inhibitor programs are still on track to start Phase
1 clinical trials in 2H2024, the Adva-27a program has been delayed (see below for
details).
We see Sunshine Biopharma as being on the verge of putting together a string of
quarters with growing revenues from its generic (and OTC) drug business ramping
up from $4.3 million in 2022 to an estimated $22.5 million in 2023, $44.4 million
in 2024 and $100 million in 2025. We confirm our BUY recommedation for SBFM
shares and our $3 Target Price.
https://sunshinebiopharma.com/analysts-coverage/
They (SBFM management) up'd the ratio because the PPS recently dropped from $.25 to $.05, but they have failed to address WHY the PPS has continuously dropped since the original Nasdaq listing. Aegis Capital has been involved since the original listing (and more recently) and apparently when they are involved the price goes down. It went down from $.25 to $.05 after their latest involvement.
Not sure what the volume was about today. Thought it might get back to $.20, but not holding my breath.
Suckered again! 1/200 RS then increasing the share count.Dilution,dilution and more dilution.April you will have a 12 to 15 dollar stock.By June you will have a 5 dollar stock with many more shares.I don't know why they let you vote on these things,your vote means nothing.Never was going to be 2/1 or even 20/1.One guy,your CEO,made it 200/1.This is how they steal your money,and it's legal.Good luck and good trading.
probably be a post REVERSE SPLIT squeezer,,,,
https://ih.advfn.com/stock-market/NASDAQ/sunshine-biopharma-SBFM/stock-news/93428710/form-pre-14c-other-preliminary-information-state
Front loader exit late....dammm
SBFM 600 million volume 160% up
SBFM preparing for 1 Dollar share price
This is why they belong in Jail
SBFM: For decades, looming Reverse Splits --- let alone the actual SPLIT itself --- would DESTROY the price & reputation of ANY stock, on ANY market place. But now, such can (sometimes) make them SOAR!!! GO-FIGURE!!!
SBFM loading 400 million volume
Buyback and improve balance sheet!
Sunshine Biopharma, Inc. recently reacquired warrants for over 21 million shares of its common stock through two separate agreements, spending a total of approximately $3.14 million. The deals involved buying back May 2023 Warrants for over $2.36 million and April 2022 Warrants at $0.08 each, adding up to $778,055. These transactions led to the cancellation and termination of the warrants, signaling a strategic move by the company to manage its outstanding securities.
SBFM: And we are BOTH rendered the FOOLS today!!!
SBFM: Yep!! Just JUNK firm, but soared during that Covid stuff of years gone bye now.
Automated wash trading. Don’t get trapped when they turn their computers off.
SBFM: But SOARING anyway!!! (Already, trading-pro's with some bucks, have scalped this crap for 5-to-10K profits in the PRE-M!!!)
SBFM: And all based upon the NEW 'theory' that a REVERSE SPLIT to a monster-diluted stock will nevertheless "lower the FLOAT' and, as such, "reduce the SUPPLY" of shares and, as such, the World will rush to buy-them-up!!! LAUGH MY MUTHA FLUCKIN' ASS OFF!!!!! (Oh, but MAYBE this P.O.S. company has a CURE FOR CANCER??????? While doing 'business' out of a MAIL-RECEIVING-BOX????)
Per the last 8K (see link below) it will occur 20 days after SBFM mails the Definitive Information Statement to shareholders. The main reason for the RS is to meet the Nasdaq minimum bid price so they don't get delisted (which was going to occur this week). They are appealing so they now have until April 25th when there will be a hearing.
So, looks like it is likely to occur later in March or early April.
https://sunshinebiopharma.com/wp-content/uploads/20240228_SBFM_8K.pdf
When does the split take place?
I thought they were on to something with the mice, speculating 1000%
Followers
|
764
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
113568
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
SUNSHINE BIOPHARMA INC
ANTI CANCER DRUGS
ANTI CORONA VIRUS RESEARCH
SBFM Transfer Agent
Corporate Stock Transfer
3200 Cherry Creek Dr. South
Suite 430
Denver, CO 80209
(303) 282 - 4800 p
(303) 282 - 5800 f
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |